Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (OTC PINK:SBFM) has successfully paid off over $100,000 in convertible notes, aiming to reduce dilution and enhance shareholder value. The CFO, Camille Sebaaly, expressed commitment to operational growth and prioritizing shareholders' interests. The company continues its development on SBFM-PL4, a COVID-19 treatment in collaboration with the University of Georgia, and Adva-27a, an anticancer compound effective against multidrug-resistant cancers. Clinical trials for Adva-27a are planned at McGill University.
Sunshine Biopharma Inc. (OTC PINK:SBFM) announced receiving the third tranche of $800,000 from a $2,000,000 financing agreement with RB Capital Partners Inc. This funding supports the priority development of their Coronavirus treatment and clinical advancement of Adva-27a, an anticancer drug targeting pancreatic cancer. The company aims to combat SARS-CoV-2 through new molecules that inhibit viral replication. Ongoing testing and collaboration with the University of Georgia are key aspects of their development strategy.
Sunshine Biopharma (OTC PINK:SBFM) is advancing its Anti-Coronavirus drug development amidst the ongoing pandemic. Recognizing the necessity for effective treatments alongside vaccines, the company emphasizes the importance of an oral treatment option. Sunshine Biopharma has filed a provisional patent for novel compounds inhibiting Coronavirus proteases, with lead candidate SBFM-PL4 currently in in vitro testing. Additionally, the company is developing Adva-27a, an anticancer drug showing efficacy against multidrug-resistant cancers, with clinical trials planned at McGill University.
Sunshine Biopharma Inc. (OTC PINK:SBFM) has entered into a collaboration agreement with a Montreal-based company to advance its anticancer compound, Adva-27a. This partnership aims to develop chemical synthesis procedures and test the compound on various cancer cells. Following successful cell culture tests, mice studies will be conducted to prepare for clinical trials targeting Stage IV pancreatic cancer at McGill University’s Jewish General Hospital in Montreal. Adva-27a has shown effectiveness against multidrug-resistant cancer cells, including those from pancreatic cancer.
Sunshine Biopharma Inc. (OTC PINK:SBFM) announced it has secured a second tranche of funding totaling $550,000 from RB Capital Partners under a $2 million financing agreement. The funds will support the development of its Coronavirus treatment and the clinical development of Adva-27a, its lead anticancer drug. SBFM-PL4, a lead compound targeting Coronavirus proteases, is currently progressing through testing phases in collaboration with the University of Georgia. The company is also conducting trials for Adva-27a aimed at treating multidrug-resistant cancers, including pancreatic cancer.
Sunshine Biopharma (OTC PINK:SBFM) announced a collaboration with the University of Georgia to advance its SBFM-PL4 anti-coronavirus compound. The agreement aims to evaluate SBFM-PL4, a protease inhibitor targeting SARS-CoV-2, through in vitro tests, followed by cell culture and animal trials before human clinical testing. This partnership is focused on developing new treatments for COVID-19, which has significantly impacted global health. Sunshine is also developing its anticancer drug, Adva-27a, targeting multidrug-resistant cancer cells.
Sunshine Biopharma Inc. (OTC PINK:SBFM) has identified a lead compound from its library of Coronavirus protease inhibitors following screening at the University of Georgia. This lead compound targets SARS-CoV-2's papain-like protease, which is essential for viral replication. The company plans to proceed with in vitro tests to evaluate the compound's efficacy against COVID-19. Sunshine is also developing Adva-27a, an anti-cancer drug effective against resistant cancer cells, with trials planned at McGill University.
Sunshine Biopharma (OTC PINK:SBFM) announced it has received the first tranche of $250,000 from a financing agreement with RB Capital Partners to secure a minimum of $2 million. The funding will aid in the development of a Coronavirus treatment and the anticancer compound Adva-27a targeting pancreatic cancer. The convertible promissory notes will have a 5% interest rate and a maturity date of two years, convertible to shares at $0.30 or market value, whichever is higher. The clinical trials for Adva-27a are planned at McGill University.
Sunshine Biopharma (OTC PINK:SBFM) has successfully synthesized four potential inhibitors targeting the Coronavirus protease, a crucial component for the virus's replication. This advancement stems from a recently filed patent for small molecules aimed at treating Coronavirus infections, including COVID-19. The next steps involve analyzing the binding affinity of these compounds to the SARS-CoV-2 papain-like protease, selecting a lead candidate for further development. Sunshine is also advancing its anticancer drug, Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells.